Adults with pathogenic MC4R mutations have increased final height and thereby increased bone mass

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

Adults with pathogenic MC4R mutations have increased final height and thereby increased bone mass. / Iepsen, Eva W.; Zhang, Jinyi; Hollensted, Mette; Madsbad, Sten; Hansen, Torben; Holst, Jens J; Jørgensen, Niklas R; Holm, Jens-Christian; Torekov, Signe S.

I: Journal of Bone and Mineral Metabolism, Bind 38, Nr. 1, 2020, s. 117-125.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Iepsen, EW, Zhang, J, Hollensted, M, Madsbad, S, Hansen, T, Holst, JJ, Jørgensen, NR, Holm, J-C & Torekov, SS 2020, 'Adults with pathogenic MC4R mutations have increased final height and thereby increased bone mass', Journal of Bone and Mineral Metabolism, bind 38, nr. 1, s. 117-125. https://doi.org/10.1007/s00774-019-01034-8

APA

Iepsen, E. W., Zhang, J., Hollensted, M., Madsbad, S., Hansen, T., Holst, J. J., Jørgensen, N. R., Holm, J-C., & Torekov, S. S. (2020). Adults with pathogenic MC4R mutations have increased final height and thereby increased bone mass. Journal of Bone and Mineral Metabolism, 38(1), 117-125. https://doi.org/10.1007/s00774-019-01034-8

Vancouver

Iepsen EW, Zhang J, Hollensted M, Madsbad S, Hansen T, Holst JJ o.a. Adults with pathogenic MC4R mutations have increased final height and thereby increased bone mass. Journal of Bone and Mineral Metabolism. 2020;38(1):117-125. https://doi.org/10.1007/s00774-019-01034-8

Author

Iepsen, Eva W. ; Zhang, Jinyi ; Hollensted, Mette ; Madsbad, Sten ; Hansen, Torben ; Holst, Jens J ; Jørgensen, Niklas R ; Holm, Jens-Christian ; Torekov, Signe S. / Adults with pathogenic MC4R mutations have increased final height and thereby increased bone mass. I: Journal of Bone and Mineral Metabolism. 2020 ; Bind 38, Nr. 1. s. 117-125.

Bibtex

@article{5c64e7aae86c4d2e8b946e13780301aa,
title = "Adults with pathogenic MC4R mutations have increased final height and thereby increased bone mass",
abstract = "Pathogenic mutations in the melanocortin-4 receptor (MC4R) are associated with obesity, increased linear growth, and higher bone mass in children, and rodent studies have indicated an effect of the MC4R on bone turnover. Furthermore, GLP-1 receptor agonists (GLP-1 RAs) may influence bone metabolism. However, these associations have not been assessed in adults with pathogenic MC4R mutations. Thus, we wished to assess the impact of the MC4R on bone mass and metabolism. Secondly, we wished to investigate the impact of the GLP-1 RA liraglutide on bone mass in adults with pathogenic MC4R mutations. 17 patients with obesity-causing MC4R mutations (BMI: 35.5 ± 7.6) and 35 matched control participants with common obesity (BMI: 34.3 ± 7.1) underwent a DEXA scan for assessment of bone mineral density (BMD), bone mineral apparent density [BMAD = (BMD/√(bone area)], and bone turnover markers (BTMs). Individuals with a BMI above 28 (14 MC4R mutation carriers and 28 matched control participants) underwent 16 weeks treatment with liraglutide 3.0 mg. The MC4R group had higher BMD [mean difference: 0.065 g/m2 (- 0.008 to 0.138), p = 0.03], but BMAD and BTMS were not different compared to the control group. In response to liraglutide, BMAD increased in the control group, compared to no change in the MC4R group [mean group difference: 0.0007 (0.0001-0.001), p = 0.04]. In conclusion, BMD is increased in MC4R causal obesity compared to common obesity, but when corrected for body size (BMAD), bone mass was not increased, and no evidence of an influence of the MC4R on bone metabolism in adults was found. Liraglutide treatment did not change bone metabolism in MC4R causal obesity, but increased bone mass as measured by BMAD in common obesity.",
author = "Iepsen, {Eva W.} and Jinyi Zhang and Mette Hollensted and Sten Madsbad and Torben Hansen and Holst, {Jens J} and J{\o}rgensen, {Niklas R} and Jens-Christian Holm and Torekov, {Signe S}",
year = "2020",
doi = "10.1007/s00774-019-01034-8",
language = "English",
volume = "38",
pages = "117--125",
journal = "Journal of Bone and Mineral Metabolism",
issn = "0914-8779",
publisher = "Springer",
number = "1",

}

RIS

TY - JOUR

T1 - Adults with pathogenic MC4R mutations have increased final height and thereby increased bone mass

AU - Iepsen, Eva W.

AU - Zhang, Jinyi

AU - Hollensted, Mette

AU - Madsbad, Sten

AU - Hansen, Torben

AU - Holst, Jens J

AU - Jørgensen, Niklas R

AU - Holm, Jens-Christian

AU - Torekov, Signe S

PY - 2020

Y1 - 2020

N2 - Pathogenic mutations in the melanocortin-4 receptor (MC4R) are associated with obesity, increased linear growth, and higher bone mass in children, and rodent studies have indicated an effect of the MC4R on bone turnover. Furthermore, GLP-1 receptor agonists (GLP-1 RAs) may influence bone metabolism. However, these associations have not been assessed in adults with pathogenic MC4R mutations. Thus, we wished to assess the impact of the MC4R on bone mass and metabolism. Secondly, we wished to investigate the impact of the GLP-1 RA liraglutide on bone mass in adults with pathogenic MC4R mutations. 17 patients with obesity-causing MC4R mutations (BMI: 35.5 ± 7.6) and 35 matched control participants with common obesity (BMI: 34.3 ± 7.1) underwent a DEXA scan for assessment of bone mineral density (BMD), bone mineral apparent density [BMAD = (BMD/√(bone area)], and bone turnover markers (BTMs). Individuals with a BMI above 28 (14 MC4R mutation carriers and 28 matched control participants) underwent 16 weeks treatment with liraglutide 3.0 mg. The MC4R group had higher BMD [mean difference: 0.065 g/m2 (- 0.008 to 0.138), p = 0.03], but BMAD and BTMS were not different compared to the control group. In response to liraglutide, BMAD increased in the control group, compared to no change in the MC4R group [mean group difference: 0.0007 (0.0001-0.001), p = 0.04]. In conclusion, BMD is increased in MC4R causal obesity compared to common obesity, but when corrected for body size (BMAD), bone mass was not increased, and no evidence of an influence of the MC4R on bone metabolism in adults was found. Liraglutide treatment did not change bone metabolism in MC4R causal obesity, but increased bone mass as measured by BMAD in common obesity.

AB - Pathogenic mutations in the melanocortin-4 receptor (MC4R) are associated with obesity, increased linear growth, and higher bone mass in children, and rodent studies have indicated an effect of the MC4R on bone turnover. Furthermore, GLP-1 receptor agonists (GLP-1 RAs) may influence bone metabolism. However, these associations have not been assessed in adults with pathogenic MC4R mutations. Thus, we wished to assess the impact of the MC4R on bone mass and metabolism. Secondly, we wished to investigate the impact of the GLP-1 RA liraglutide on bone mass in adults with pathogenic MC4R mutations. 17 patients with obesity-causing MC4R mutations (BMI: 35.5 ± 7.6) and 35 matched control participants with common obesity (BMI: 34.3 ± 7.1) underwent a DEXA scan for assessment of bone mineral density (BMD), bone mineral apparent density [BMAD = (BMD/√(bone area)], and bone turnover markers (BTMs). Individuals with a BMI above 28 (14 MC4R mutation carriers and 28 matched control participants) underwent 16 weeks treatment with liraglutide 3.0 mg. The MC4R group had higher BMD [mean difference: 0.065 g/m2 (- 0.008 to 0.138), p = 0.03], but BMAD and BTMS were not different compared to the control group. In response to liraglutide, BMAD increased in the control group, compared to no change in the MC4R group [mean group difference: 0.0007 (0.0001-0.001), p = 0.04]. In conclusion, BMD is increased in MC4R causal obesity compared to common obesity, but when corrected for body size (BMAD), bone mass was not increased, and no evidence of an influence of the MC4R on bone metabolism in adults was found. Liraglutide treatment did not change bone metabolism in MC4R causal obesity, but increased bone mass as measured by BMAD in common obesity.

U2 - 10.1007/s00774-019-01034-8

DO - 10.1007/s00774-019-01034-8

M3 - Journal article

C2 - 31471646

VL - 38

SP - 117

EP - 125

JO - Journal of Bone and Mineral Metabolism

JF - Journal of Bone and Mineral Metabolism

SN - 0914-8779

IS - 1

ER -

ID: 237104841